Production (Stage)
Telomir Pharmaceuticals, Inc.
TELO
$2.09
-$0.01-0.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.80% | -50.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.70% | -51.63% | |||
| Operating Income | 24.70% | 51.63% | |||
| Income Before Tax | 24.79% | 51.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.79% | 51.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.79% | 51.62% | |||
| EBIT | 24.70% | 51.63% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 25.08% | 51.71% | |||
| Normalized Basic EPS | 25.04% | 51.70% | |||
| EPS Diluted | 25.08% | 51.71% | |||
| Normalized Diluted EPS | 25.04% | 51.70% | |||
| Average Basic Shares Outstanding | 0.34% | 0.17% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||